Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,77
KB1,26
PKN105,8106,251,00
Msft-0,77
IBM-0,52
DCX70,9770,99-0,15
PFE2,01
15.12.2017 1:36:41
Indexy online
AD Index online
select
AD Index online
 

  • 14.12.2017
Ultragenyx Pharm (NASDAQ Cons)
Závěr k 14.12.2017 Změna (%) Změna (USD) Objem obchodů (ks)
44,02 -2,59 -1,17 313 607
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 15.12.2017
Popis společnosti
Obecné informace
Název společnostiUltragenyx Pharmaceutical Inc
TickerRARE
Kmenové akcie:Ordinary Shares
RICRARE.O
ISINUS90400D1081
Prioritní akcieConv. Pref. Shrs
Prioritní akcieConv. Pref. Shrs
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.9.2017
Počet zaměstnanců k 31.12.2016 376
Akcie v oběhu k 30.10.2017 42 589 056
MěnaUSD
Kontaktní informace
Ulice60 Leveroni Ct
MěstoNOVATO
PSČ94949-5746
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon14 154 838 800
Fax14154838810

Business Summary: Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
Financial Summary: BRIEF: For the nine months ended 30 September 2017, Ultragenyx Pharmaceutical Inc revenues increased 55% to $198K. Net loss increased 26% to $220.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other Research and Development increase of 27% to $141.6M (expense), General and administrative increase of 33% to $42.2M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 15.12.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardDaniel Welch59
President, Chief Executive Officer, DirectorEmil Kakkis57
Chief Financial Officer, Executive Vice PresidentShalini Sharp42
President - Research and DevelopmentSunil Agarwal4717.4.201725.8.2014
Executive Vice President, General CounselKarah Parschauer3920.6.201620.6.2016
Chief Commercial Officer and Executive Vice PresidentJayson Dallas493.8.2015
Chief Technical Operations Officer, Executive Vice PresidentDennis Huang524.6.2015
Chief Business Officer, Executive Vice PresidentThomas Kassberg56
Chief Quality Operations Officer and Executive Vice President Analytical Sciences and ResearchJohn Pinion5113.7.2015